Updated from 8:11 a.m. EDT

Eli Lilly ( LLY) Thursday reported double-digit sales growth for the sixth straight quarter, thanks to both new and established drugs.

Indianapolis-based Lilly said net income fell 5% to $656.9 million, or 60 cents a share, vs. $692.2 million, or 64 cents a share in the year-ago period. But excluding charges, profit rose 7% to $738.7 million, or 68 cents a share.

The consensus estimate was for net income of $735.4 million, or 68 cents a share, on revenue of $3.4 billion, according to Thomson First Call.

Revenue rose to $3.56 billion, vs. $3.09 billion a year ago.

In terms of future guidance, Lilly expects EPS of 67 cents to 68 cents in the third quarter and $2.80 to $2.85 for the full year, excluding charges. The consensus estimates are 71 cents and $2.82, respectively.

Sales of Zyprexa, an anti-psychotic, led the way in the quarter, racking up $1.21 billion in sales, up 16% from a year ago. International sales jumped 31%. Lilly's group of diabetes treatments rose 5% from the year-ago period to $674.9 million.

The company said newer products, including its erectile dysfunction drug Cialis, contributed $350.4 million in sales in 2004, accounting for 10% of total revenue. Lilly is widely considered to have one of the best product pipelines in the industry.

Total worldwide sales for Cialis, the impotence drug that reached the U.S. market in late November, grew to $137.2 million, up from $37.4 million a year ago and $108.3 million in the first quarter. Cialis was developed by Icos ( ICOS) and is marketed in North American and European markets by a joint venture of the two companies and in other markets by Lilly. U.S. sales hit $50.8 million in the April-June period.

Lilly and Icos have been heavily promoting Cialis in an effort to cut deeper into the market share of the longtime leader, Viagra, which is made by Pfizer ( PFE). Pfizer on Wednesday said worldwide sales of its drug fell in the second quarter for the second quarter in a row.

Lilly's first-quarter earnings and revenue topped Wall Street estimates by a healthy margin. Excluding one-time charges, Lilly earned $762.7 million, or 70 cents a share, for the three months ended March 31. Revenue advanced 17% to $3.38 billion.

Lilly shares fell 11 cents, or 0.2%, to $65.17

Second-quarter earnings results from the major drugmakers have been mixed. Industry No. 1 Pfizer beat analysts forecasts by a penny Wednesday, as its stable of drugs posted broad-based gains. Merck ( MRK ) met expectations, while profit and revenue slipped a bit. Schering-Plough fell short of expectations in posting a tiny loss. Wyeth ( WYE ) surpassed forecasts as revenue rose 13%. Swiss-based Novartis ( NVS ) easily beat consensus estimates as net income rose 19%. Bristol-Myers Squibb ( BMY) reports July 29.